In July 2020, gammaCore Sapphire™ CV (nVNS) receives EUA to treat patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow.
In July 2020, gammaCore Sapphire™ CV (nVNS) receives EUA to treat patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow.